Instruction for use: Enzaprost-F

Dosage Form:Solution for intraamnial administration

Active substance: Dinoprost*

ATX

G02AD01 Dinoprost

Pharmacotherapeutic groups:

Prostaglandins, thromboxanes, leukotrienes and their antagonists

Uterotonics

The nosological classification (ICD-10)

O04 Medical abortion: Artificial abortion; Medical abortion; Abortion artificial; Vacuum aspiration; Abortion

O62.2 Other types of weakness in labor: Atony of the uterus; Weakness of labor; Reduced uterine tone; Induction of labor; Induction of labor with full term pregnancy; Induction of labor with full term or almost full pregnancy; Activation of labor

Composition and release form

1 ml of solution for injection contains dinoprosta 5 mg; In ampoules of 1 ml, in a cardboard box 5 pcs.

Pharmacology

Mode of action - stimulating generic activity.

It is an analog of the F2alpha PG. Increases the tone of the myometrium and expands the cervix.

Indications for the Enzaprost-F

Abortion with intrauterine fetal death in the I-II trimester, in the case of severe fetal disease (anencephaly, hydrocephalus, Amelia); the excitement of labor in connection with intrauterine fetal death (in late pregnancy), premature discharge of water, the primary generic weakness, placental delivery phase; Stimulation and stimulation of labor during artificially induced childbirth.

Contraindications

Bronchoobstructive syndrome, ulcerative colitis (exacerbation and remission), sickle cell disease, glaucoma, hypertension (160/100 mm Hg or higher), epilepsy, scars on the uterus (cesarean fibroid removal history, etc. .), Congenital malformations of the uterus, uterine myoma, heart failure, active pulmonary tuberculosis, severe liver dysfunction.

Side effects

Nausea, vomiting, diarrhea, intestinal colic; Painful contractions in the lower abdomen associated with increased uterine contractility; Tachycardia, headache, temporary increase or decrease in blood pressure; Dyspnea due to bronchospasm; Sweating, a sense of fainting, allergic reactions.

Interaction

The effect is enhanced by oxytocin and ergometrine.

Dosing and Administration

IV, extra- or intraamnially. For abortion ekstraamnialno introduced into the uterine cavity (via the catheter) during pregnancy from 0 to 6 weeks - 3.5 mg, in terms of 7 to 14 weeks - 5 mg, and after 5-6 h an additional 5-10 mg. If pregnancy from 15 to 28 weeks preferably administered intra-amniotic 25 mg (suction after a few milliliters of amniotic fluid and its lack of blood impurities) in the absence of effect - again after 8-12 hours to induce childbirth -. / Drip in a dose and With a rate that depends on the specific clinical situation and the response to the therapy; As a rule, the total dose is 1-5 mg and the rate of administration is 9-15 μg / min.

Precautionary measures

After the birth stimulation induced by Enzaprost F, an adequate examination is necessary to determine the completeness of the completion of labor.

Storage conditions of Enzaprost-F

In a cool place, at a temperature of 5-15 ° C.

Keep out of the reach of children.

Shelf life of Enzaprost-F

3 years.

Do not use beyond the expiration date printed on the package.